Tom Heyman is President, Johnson & Johnson Development Corporation (JJDC), part of Johnson & Johnson Innovation. As head of JJDC, Tom will chair the board of JJDC, which represents the oldest and most reputable corporate venture fund in the life science industry.
Tom will continue his position as CEO of Janssen Pharmaceutica NV in Belgium, and he continues to be responsible for campus leadership in Beerse, Belgium, as well as the development and execution of a long-term organizational and talent strategy. Tom was appointed Chairman of the Board of Directors, Janssen Pharmaceutica in March 2012. He is a member of the Board of Directors VOKA, the Flemish Industry Association, Belgium, and a member of the Board of Directors of Innotek. As of April 2012, he is a member of the Board of Directors and the General Assembly of IMEC.
Tom started his career with Johnson & Johnson in the Legal Department of Janssen Pharmaceutica NV in 1982, where he supported legal and licensing activities. In 1990, he became Vice-President of Corporate Development at Ortho Pharmaceutical Corporation, and was later appointed Head of Global Business Development for the Pharmaceutical Group. In his 25 years in Business Development, Tom and his Group entered into hundreds of transactions for both early and late stage Pharmaceutical products and technologies including IMBRUVUCA®, daratanumab, INVOKANA®, etc. He was also responsible for acquiring several key companies for J&J including Aragon Pharmaceuticals, Covagen and Alios Biopharma. Tom has been a member of the Pharmaceuticals Group Operating Committee (GOC), and he also served as Head of the CNS/IM Research & Early Development (RED) organization.